Pathogens . Antibody-Based Immunotherapeutic Strategies for COVID-19

[tetano]

Pathogens


. 2020 Nov 5;9(11):E917.
doi: 10.3390/pathogens9110917.
Antibody-Based Immunotherapeutic Strategies for COVID-19


Jamal Hussen ¹ , Mahmoud Kandeel ^{2 3} , Maged Gomaa Hemida ^{1 4} , Abdullah I A Al-Mubarak ¹



Affiliations

• PMID: 33167401
• DOI: 10.3390/pathogens9110917

Abstract

Global efforts to contain the coronavirus disease-2019 (COVID-19) include the development of novel preventive vaccines and effective therapeutics. Passive antibody therapies using convalescent plasma, SARS-CoV-2 (Severe-Acute-Respiratory-Syndrome-Corona-Virus-2)-specific neutralizing antibodies (NAbs), and the development of monoclonal antibodies (MAbs) are among the most promising strategies for prophylaxis and treatment of SARS-CoV-2 infections. In addition, several immunomodulatory antibodies acting via several mechanisms to boost the host immune defense against SARS-CoV-2 infection as well as to avoid the harmful overreaction of the immune system are currently under clinical trial. Our main objective is to present the current most up-to-date progress in some clinical trials registered at ClinicalTrials.gov. We highlight the pros and pitfalls of several SARS-CoV-2 antibody-based immunotherapeutics.

Keywords: COVID-19; SARS CoV-2; antibodies; clinical trials; immunotherapy.